- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00688272
Study In Healthy Subjects To Evaluate The Photo-Irritant Potential Of Eltrombopag
13. November 2017 aktualisiert von: GlaxoSmithKline
A Phase I, Double-blind, Placebo and Observer-blind Positive Controlled, Randomized, Parallel Group Study in Healthy Subjects to Investigate the Photoirritant Potential of Eltrombopag
This study is designed to investigate the safety profile and the photoirritant potential of eltrombopag in healthy subjects.
The study is placebo- and positive controlled, randomized, parallel group with three treatment arms: eltrombopag (75 mg QD), placebo, and a positive control (ciprofloxacin, 500 mg BID).
Eltrombopag will be administered in a double-blind fashion with respect to placebo and the positive control, ciprofloxacin, will be administered under observer-blinded conditions.
Twelve to fifteen subjects will be recruited into each arm, to assure total enrollment of 36 evaluable subjects.
The primary endpoint is the photosensitizing potential of eltrombopag as measured by photoirritant index (PI) and change in minimum erythemal dose (MED) in comparison with placebo.
Studienübersicht
Status
Abgeschlossen
Bedingungen
Intervention / Behandlung
Studientyp
Interventionell
Einschreibung (Tatsächlich)
36
Phase
- Phase 1
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
-
Dundee, Vereinigtes Königreich, DD1 9SY
- GSK Investigational Site
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
18 Jahre bis 65 Jahre (Erwachsene, Älterer Erwachsener)
Akzeptiert gesunde Freiwillige
Ja
Studienberechtigte Geschlechter
Alle
Beschreibung
Inclusion Criteria:
- Healthy Caucasian male or females with no clinically significant abnormality identified by the physician by evaluation of medical history, physical examination, clinical laboratory tests or 12-lead ECG.
- Subjects were adult males or females between 18 and 65 years of age, inclusive.
- All female subjects of child bearing potential agreed to commit to one of the protocol approved methods of contraception, and that they were used consistently and in accordance with both the product label and the instructions of a physician. Female participants are not permitted to use Hormonal form of contraception (combined oral contraceptive pills etc) because of its known potential to induce photosensitivity.
- All male subjects agreed to abstain completely from (or use a condom during) sexual intercourse with a pregnant or lactating female.
- All male subjects with partner(s) who is /are able to have children agreed to use condom with spermicide from screening until 90 days after the last dose of study medication. In addition, their partner (s) had to also use one of the following forms of contraception until 90 days after last date of study medication:
- Hormonal contraception i.e. the pill or hormones given by injection or given under the skin.
- Diaphragm with spermicide
- Cervical cap or female condoms.
- An intrauterine device (a coil micro-insert).
- Intrauterine system (IUS) e-g Mirena coil
- Tubal ligation
- Body weight greater than or equal to 50 kg and body mass index within the range 19-29.9 kg/m2.
- A signed and dated written informed consent was obtained for the subject.
- Skin Type 1, 2, or 3 according to the dermatological scale presented in the study protocol (see Modular Appendices).
- Negative test for porphyrins, ANF, anti-Ro and anti-La (tests for lupus erythematosus) at screening.
- Liver function tests (LFTs; AST, ALT, ALP, bilirubin, gamma-GT) within the reference range, or deviations that were not considered clinically significant at screening by the investigator.
- Subjects who had a normal value of MED in comparison with the normal population databank at the photobiology unit, Dundee.
- The subject was able to understand and comply with protocol requirements and time tables, instructions and protocol-stated restrictions Exclusion Criteria
- Any abnormality identified on the screening medical assessment that in the opinion of the investigator and GlaxoSmithKline medical monitor could have been associated with an increased rish to the subject or could have interfered with study procedures.
- Subjects who had any sun or sunbed exposure to the skin of the back during the four weeks prior to the screening period.
- Subjects with history of polymorphic light eruption.
- Subjects who had a history of sensitivity to ciprofloxacin, any of the study medications or components thereof.
- Subjects with history of malignant melanoma in a first degree family member.
- Subjects with history of Gilbert Syndrome.
- Subjects with history of deep vein thrombosis or any other thromboembolic event.
- Subjects with history of sensitivity to heparin, or heparin-induced thrombocytopenia.
- Subjects with history of platelet clumping that prevents reliable measurement of platelet counts.
- Subjects with history of thrombocytopenia or bleeding due to abnormal platelet number or function.
- Subjects with C-reactive protein (CRP) that is elevated above normal range and considered clinically significant at screening.
- Subjects with history of myocardial infarction, stroke or sudden unexplained death in a first degree family member under the age of 60 years.
- Subjects with clotting factor abnormalities associated with hypercoagulability, specifically Factor V Leiden, Protein C, or Protein S deficiency, or antithrombin III deficiency.
- Subjects with haemoglobin, white blood cells, platelet count or reticulocyte count that are outside the reference range and considered clinically significant at screening by the investigator.
- Subjects with positive test for HIV, hepatitis B virus or hepatitis C virus.
- Subjects with positive urine drug screen including alcohol.
- Subjects with history of alcohol/drug abuse or dependence within 12 months of screening.
- History of regular alcohol consumption exceeding average weekly intake of greater than 21 units or an average daily intake of greater than three units (males) or an average weekly intake of greater than 14 units or an average daily intake of greater than two units (females). One unit is equivalent to a half-pint (220 mL) of beer/lager or one (25 mL) measure of spirits or one glass (125 mL) of wine.
- Subjects who could not refrain from smoking during the study period from Day-1 through the completion of follow-up assessments.
- Subjects who had received treatment with an investigational drug within 30 days or five half-lives (whichever is longer) preceding the first dose of study medication.
- Subjects who had been exposed to more than four new chemical entities within 12 months prior to the first dosing day.
- Subjects who had taken any prescription or non-prescription drugs (including aspirin and NSAIDs), vitamins, herbal and dietary supplements, or any herbal remedies containing St. John's Wort within seven days (or 14 days if the drug is a potential enzyme inducer) or five half-lives (whichever is longer) prior to the first dose of study medication and through the completion of follow-up assessments. By exception, acetaminophen (or, paracetamol) at doses of less than or equal to 2 g/day and stable thyroid replacement therapy was allowed.
- Consumption of antacids (e.g., Maalox, Mylanta, Amphogel, Milk of Magnesia or TUMS™) within 48 h of the first dose of study medication and until the completion of follow-up assessments.
Subjects who had an clinically significant skin/allergic disease, including photo-allergy (excluding non
- active hay fever).
- Subjects with multiple tattoos which may have obscured skin reactions or which restricted the skin surface area available for testing.
- Subjects had to abstain from consumption of grapefruit, pomelo or Seville oranges from screening until the completion of follow-up assessments
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Arm 1
Eltrombopag 75 mg QD x 6 days
|
Given QD x 6 days
Andere Namen:
|
Aktiver Komparator: Arm 2
Ciprofloxicin 500mg BID x 6 days
|
Given 500mg BID x 6 days
|
Placebo-Komparator: Arm 3
Placebo QD x 6 days
|
Given QD x 6 days
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Evaluate the photosensitizing potential, as measured by photoirritant index and change from baseline in minimum erythemal dose, of eltrombopag when dosed orally at 75 mg QD as compared to placebo and ciprofloxacin 500 mg BID.
Zeitfenster: Screening - Day 8
|
Screening - Day 8
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Severity of phototoxic response Concentration of porphyrins, ANF, anti-Ro, and anti-La as measured on Day 6.
Zeitfenster: Day 6
|
Day 6
|
Vital signs (blood pressure, heart rate, respiration rate and body temperature) taken after resting semi-supine position for at least 10 minutes;
Zeitfenster: Screening, Days 1,2,3,4,5,6,7, and f/u
|
Screening, Days 1,2,3,4,5,6,7, and f/u
|
Clinical laboratory tests
Zeitfenster: Screening, Day 1, 7 and f/u
|
Screening, Day 1, 7 and f/u
|
Assessment of AEs.
Zeitfenster: Continuous trhoughout the study.
|
Continuous trhoughout the study.
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Publikationen und hilfreiche Links
Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Tatsächlich)
2. Juni 2008
Primärer Abschluss (Tatsächlich)
25. September 2008
Studienabschluss (Tatsächlich)
25. September 2008
Studienanmeldedaten
Zuerst eingereicht
28. Mai 2008
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
30. Mai 2008
Zuerst gepostet (Schätzen)
2. Juni 2008
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
17. November 2017
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
13. November 2017
Zuletzt verifiziert
1. November 2017
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Pathologische Prozesse
- Erkrankungen des Immunsystems
- Autoimmunerkrankungen
- Hämatologische Erkrankungen
- Blutung
- Hämorrhagische Störungen
- Blutgerinnungsstörungen
- Hautmanifestationen
- Thrombozytopenie
- Erkrankungen der Blutplättchen
- Thrombotische Mikroangiopathien
- Purpura
- Purpura, Thrombozytopenie
- Purpura, thrombozytopenisch, idiopathisch
- Molekulare Mechanismen der pharmakologischen Wirkung
- Antiinfektiva
- Enzym-Inhibitoren
- Antineoplastische Mittel
- Topoisomerase-II-Inhibitoren
- Topoisomerase-Inhibitoren
- Antibakterielle Mittel
- Cytochrom-P-450-Enzym-Inhibitoren
- Cytochrom P-450 CYP1A2-Inhibitoren
- Ciprofloxacin
Andere Studien-ID-Nummern
- TRA106914
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Purpura, thrombozytopenisch, idiopathisch
-
Insel Gruppe AG, University Hospital BernSwiss National Science Foundation; Mach Gaensslen Foundation; Baxalta Innovations...RekrutierungThrombotische thrombozytopenische Purpura | Angeborene thrombotische thrombozytopenische Purpura | Familiäre thrombotische thrombozytopenische Purpura | Thrombotisch-thrombozytopenische Purpura, angeboren | Upshaw-Schulman-SyndromVereinigte Staaten, Österreich, Tschechien, Deutschland, Japan, Norwegen, Schweiz
-
Turkish Hematology AssociationSanofiRekrutierungTTP – Thrombotisch-thrombozytopenische PurpuraTruthahn
-
University of CologneRekrutierungErworbene thrombotische thrombozytopenische PurpuraDeutschland
-
Peking Union Medical College HospitalNoch keine RekrutierungThrombotische thrombozytopenische Purpura, erworbenChina
-
Fundación Española de Hematología y HemoterapíaRekrutierungErworbene thrombotische thrombozytopenische PurpuraSpanien, Portugal
-
University of CologneRekrutierungErworbene thrombotische thrombozytopenische PurpuraDeutschland
-
Harbour BioMed (Guangzhou) Co. Ltd.RekrutierungPrimäre immunthrombozytopenische PurpuraChina
-
Novartis PharmaceuticalsAbgeschlossenImmunthrombozytopenische Purpura (ITP)Spanien, Italien, Griechenland, Schweiz, Vereinigtes Königreich, Frankreich, Truthahn, Russische Föderation, Brasilien, Österreich, Mexiko, Oman, Chile, Japan, Vereinigte Staaten
-
TakedaVerfügbarThrombotisch-thrombozytopenische Purpura (TTP)
-
Ablynx, a Sanofi companyAbgeschlossenErworbene thrombotische thrombozytopenische PurpuraVereinigte Staaten, Österreich, Belgien, Frankreich, Deutschland, Israel, Italien, Spanien, Schweiz, Vereinigtes Königreich, Bulgarien, Rumänien, Australien
Klinische Studien zur Eltrombopag
-
Novartis PharmaceuticalsAbgeschlossenPurpura, thrombozytopenisch, idiopathischRussische Föderation
-
Weill Medical College of Cornell UniversityNovartisBeendetImmunthrombozytopenieVereinigte Staaten
-
Institute of Hematology & Blood Diseases Hospital...Xijing Hospital; Xi'an Central Hospital; The Second Hospital of Hebei Medical... und andere MitarbeiterAktiv, nicht rekrutierendZuvor behandelte primäre ImmunthrombozytopenieChina
-
Tel-Aviv Sourasky Medical CenterNovartisRekrutierungB-Zell-Lymphom | CART-BehandlungIsrael
-
Gruppo Italiano Malattie EMatologiche dell'AdultoAbgeschlossenPrimacy ImmunthrombozytopenieItalien
-
Novartis PharmaceuticalsAbgeschlossenPurpura, thrombozytopenisch, idiopathisch
-
Nanfang Hospital of Southern Medical UniversityGuangzhou First People's Hospital; Second Affiliated Hospital, Sun Yat-Sen University und andere MitarbeiterUnbekanntAkute myeloische Leukämie | Thrombozytopenie | EltrombopagChina
-
IRCCS Policlinico S. MatteoAbgeschlossen
-
Dana-Farber Cancer InstituteBeendetMultiples Myelom | ThrombozytopenieVereinigte Staaten